<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152866">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109966</url>
  </required_header>
  <id_info>
    <org_study_id>CT0140PAICE</org_study_id>
    <nct_id>NCT01109966</nct_id>
  </id_info>
  <brief_title>An Elimination Diet Using a New Amino Acid Based Formula: Immunological and Clinical Effects in Cow's Milk Allergy</brief_title>
  <official_title>A Prospective, Double Blind Randomised Controlled Trial to Evaluate the Immunological Benefits and Clinical Effects of an Elimination Diet Using an Amino Acid Based Formula (AAF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutricia Liverpool</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nutricia Liverpool</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether a new version of an amino acid based
      formula improves tolerance to milk in cow's milk allergic infants/young children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants with CMA cannot tolerate proteins contained in milk, although they are able to
      tolerate amino acids which are the 'building blocks' of proteins. Unlike standard infant
      formulas which are made from milk proteins, amino acid formulas (AAF) are made from
      nonallergenic aminoacids plus all the other nutrients required to support growth and
      development.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the development of oral tolerance in infants with IgE mediated CMA on control or test AAF.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate maturation of the GI immune system in IgE mediated CMA To confirm that the test formula is effective in the dietary management of CMA To assess frequency of other allergies</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Allergy</condition>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>Amino acid based formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomised to one of two arms:
Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New amino acid based formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomised to one of two arms:
Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Special Medical Food</intervention_name>
    <description>Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.
Infants should typically consume the following amounts of formula during the study &gt; 500mls/day up to 12 months of age &gt; 400mls/day between 12 and 18 months of age &gt; 300mls/day over 18 months of age.</description>
    <arm_group_label>Amino acid based formula</arm_group_label>
    <other_name>Amino acid based formula, Neocate LCP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Special Medical Food</intervention_name>
    <description>Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.
Infants should typically consume the following amounts of formula during the study &gt; 500mls/day up to 12 months of age &gt; 400mls/day between 12 and 18 months of age &gt; 300mls/day over 18 months of age.</description>
    <arm_group_label>New amino acid based formula</arm_group_label>
    <other_name>Amino acid based formula</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants ≤ 8 months of age

          -  Infants sensitised to cow's milk and diagnosed with IgE mediated cow's milk allergy
             confirmed by milk challenge or diagnosis of anaphylaxis to milk within the last 3
             months

        Exclusion Criteria:

          -  Infants less than 2500 g at birth

          -  Infants less than 37 weeks gestation

          -  Infants with severe concurrent illness

          -  Use of anti- histamines, systemic corticosteroids, systemic antibiotics or
             anti-mycotic drugs, and immuno-modulatory drugs

          -  Infants consuming less than 500ml per day of their usual formula at study entry

          -  Investigator's uncertainty about the willingness or ability of the subject to comply
             with the protocol requirements

          -  Participation in any other studies involving investigational or marketed products
             concomitantly or within two weeks prior to entry into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Beyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Charité</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>l'hôpital Necker Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Dupont, Prof.</last_name>
      <email>christophe.dupont@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Dupont, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Charité</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Beyer, PD Dr med</last_name>
      <phone>+49-(0)30-450 566037</phone>
      <email>kirsten.beyer@charite.de</email>
    </contact>
    <investigator>
      <last_name>Kirsten Beyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St.-Marien-Hospital</name>
      <address>
        <city>Bonn</city>
        <zip>53115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Lange, MD</last_name>
      <email>Lars.Lange@marien-hospital-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Lars Lange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mich Lajeunesse, MD</last_name>
      <email>mich.lajeunesse@soton.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mich Lajeunesse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Michaelis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>David Hyde Allergy Clinic - St. Mary's hospital</name>
      <address>
        <city>Newport</city>
        <state>Isle of Wight</state>
        <zip>PO30 5TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Roberts, MD</last_name>
      <email>g.c.roberts@soton.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Graham Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evelina Children's Hospital - St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Fox, MD</last_name>
      <email>adam.fox@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Adam Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle general hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Vance, MD</last_name>
      <email>Gillian.Vance@nuth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Gillian Vance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 21, 2011</lastchanged_date>
  <firstreceived_date>March 29, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Research and Development</name_title>
    <organization>Nutricia Liverpool</organization>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>Cow's Milk</keyword>
  <keyword>Infants</keyword>
  <keyword>Food Allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
